Integrated BioPharma, Inc. (INBP)

Integrated BioPharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	54.35	50.32	50.67	56.25	63.56
Revenue Growth (YoY)	8.02%	-0.70%	-9.91%	-11.51%	20.45%
Cost of Revenue	48.79	46.43	46.61	49.69	54.08
Gross Profit	5.56	3.88	4.06	6.55	9.48
Selling, General & Admin	3.54	3.63	3.94	3.81	3.7
Operating Expenses	3.54	3.63	3.94	3.81	3.7
Operating Income	2.02	0.25	0.12	2.75	5.78
Interest Expense	-0.05	-0.05	-0.01	-0.13	-0.26
Interest & Investment Income	0.09	0.07	-	-	-
Other Non Operating Income (Expenses)	0	-0	-0.01	0.01	0.06
EBT Excluding Unusual Items	2.06	0.27	0.1	2.63	5.59
Gain (Loss) on Sale of Investments	-	-	-	-0.06	0
Gain (Loss) on Sale of Assets	-	-	-	0.02	-
Other Unusual Items	-	-	-	-	1.66
Pretax Income	2.06	0.27	0.1	2.6	7.25
Income Tax Expense	1.25	0.16	0.13	-1.24	-0.77
Net Income	0.81	0.11	-0.03	3.84	8.01
Net Income to Common	0.81	0.11	-0.03	3.84	8.01
Net Income Growth	621.43%	-	-	-52.10%	95.06%
Shares Outstanding (Basic)	30	30	30	30	30
Shares Outstanding (Diluted)	31	31	30	32	32
Shares Change (YoY)	0.95%	3.08%	-7.34%	0.65%	3.07%
EPS (Basic)	0.03	0.00	-0.00	0.13	0.27
EPS (Diluted)	0.03	0.00	-0.00	0.12	0.25
EPS Growth	635.32%	-	-	-52.00%	92.31%
Free Cash Flow	1.87	0.39	1.12	3.61	2.76
Free Cash Flow Per Share	0.06	0.01	0.04	0.11	0.09
Gross Margin	10.23%	7.72%	8.01%	11.65%	14.92%
Operating Margin	3.72%	0.50%	0.24%	4.88%	9.10%
Profit Margin	1.49%	0.22%	-0.07%	6.82%	12.61%
Free Cash Flow Margin	3.45%	0.78%	2.20%	6.41%	4.33%
EBITDA	2.34	0.56	0.47	3.08	6.12
EBITDA Margin	4.30%	1.11%	0.93%	5.48%	9.63%
D&A For EBITDA	0.32	0.31	0.35	0.34	0.34
EBIT	2.02	0.25	0.12	2.75	5.78
EBIT Margin	3.72%	0.50%	0.24%	4.88%	9.10%
Effective Tax Rate	60.81%	58.21%	134.00%	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.